
	Always check on-line for validity.	Level:	
	Client Specific: Table 3 Compounds by Direct Injection Using LC/MS/MS	Work Instruction	
	Document number: T-PFAS-WI20127		
	Old Reference:		
Version: 3		Organisation level: 5-Sub-BU	
Approved by: XL3S Effective Date 05-JUN-2020	Document users: 5_EUUSLA_PFAS_Manager, 6_EUUSLA_PFAS_Analyst, 6_EUUSLA_PFAS_Data_Reviewers, 6_EUUSLA_PFAS_Management_Team, 6_EUUSLA_PFAS_Sample_Prep	Responsible: 5_EUUSLA_PFAS_Manager	

LIMS ID
14675



This documentation has been prepared by Eurofins Lancaster Laboratories Environmental LLC and its affiliates ("Eurofins"), solely for their own use. The user of this document agrees by its acceptance to return it to Eurofins upon request and not to reproduce, copy, lend, or otherwise disclose its contents, directly or indirectly, and not to use it for any other purpose other than that for which it was specifically provided. The user also agrees that where consultants or other outside parties are involved in the evaluation process, access to these documents shall not be given to said parties unless those parties also specifically agree to these conditions.

THIS DOCUMENT CONTAINS VALUABLE CONFIDENTIAL AND PROPRIETARY INFORMATION. DISCLOSURE, USE OR REPRODUCTION OF THESE MATERIALS WITHOUT THE WRITTEN AUTHORIZATION OF EUROFINS IS STRICTLY PROHIBITED. THIS UNPUBLISHED WORK BY EUROFINS IS PROTECTED BY STATE AND FEDERAL LAW OF THE UNITED STATES.

- [Revision Log](#)
- [Reference](#)
- [Cross Reference](#)
- [Scope](#)
- [Basic Principles](#)
- [Interferences](#)
- [Precaution to Minimize Method Interference](#)
- [Safety Precautions and Waste Handling](#)
- [Personnel Training and Qualifications](#)
- [Sample Collection, Preservation, and Handling](#)
- [Apparatus and Equipment](#)
- [Reagents and Standards](#)
- [Calibration](#)
- [Procedure](#)
- [Calculations](#)
- [Statistical Information/Method Performance](#)
- [Quality Assurance/Quality Control](#)

Revision Log

	Revision: <u>3</u>	Effective date: <u>This version</u>
Section	Justification	Changes
Revision Log	Formatting requirement	Removed revision logs up to the previous version
Scope	Update of Method	Removed DFSA, MMF, MTP, PPF Acid, PMPA and PEPA from target analytes. Added HFPODA and PFHpA.
Apparatus and Equipment	Enhancement	

	Always check on-line for validity.	Level:		
	Document number: T-PFAS-WI20127	Client Specific: Table 3 Compounds by Direct Injection Using LC/MS/MS		Work Instruction
	Old Reference:			
	Version: 3			Organisation level: 5-Sub-BU
Approved by: XL3S Effective Date 05-JUN-2020	Document users: 5_EUUSLA_PFAS_Manager, 6_EUUSLA_PFAS_Analyst, 6_EUUSLA_PFAS_Data_Reviewers, 6_EUUSLA_PFAS_Management_Team, 6_EUUSLA_PFAS_Sample_Prep	Responsible: 5_EUUSLA_PFAS_Manager		

	Revision: <u>3</u>	Effective date: <u>This version</u>
Section	Justification	Changes
		Add Class A PP volumetric flask information to replace Class B PP
Reagents and Standards	Update of Method	Removed DFSA, MMF, MTP, PPF Acid, PMPA and PEPA from target analytes. Added HFPODA and PFHpA. Added in section for preparation of IDA solution (13C4-PFHpA and 13C3-HFPODA)
Reference	method requirement update	updated revision date to be 1/10/19
Calibration	Method requirement update	TAF, BP4, BP5, R-EVE ICV/CCV criteria +/- 50% of true value(updated throughout section)
Procedure and QA/QC	Method requirement update	TAF, BP4, BP5, R-EVE ICV/CCV recovery criteria is 50-150% (updated throughout section)



Revision <u>2</u>	Effective Date: <u>12-APR-2019</u>	
Section	Justification	Changes
Revision Log	Formatting requirement	Removed revision logs up to the previous version
Throughout document	Update requirements	Add additional compounds requested by the client throughout the document to reflect current practice.

Reference

1. Determination of Table 3 Plus Compounds by LC/MS/MS, Chemours Fluoroproducts Analytical Method, A. Petlick, Revision date 1/10/2019
2. *Chemical Hygiene Plan*, current version.

Cross Reference



Document	Document Title
T-PEST-WI9847	Common Equations Used During Chromatographic Analyses
QA-SOP11892	Determining Method Detection Limits and Limits of Quantitation

	Always check on-line for validity.	Level:	
	Client Specific: Table 3 Compounds by Direct Injection Using LC/MS/MS	Work Instruction	
Document number: T-PFAS-WI20127			
Old Reference:			
Version: 3			
Approved by: XL3S Effective Date 05-JUN-2020	Document users: 5_EUUSLA_PFAS_Manager, 6_EUUSLA_PFAS_Analyst, 6_EUUSLA_PFAS_Data_Reviewers, 6_EUUSLA_PFAS_Management_Team, 6_EUUSLA_PFAS_Sample_Prep	Organisation level: 5-Sub-BU	Responsible: 5_EUUSLA_PFAS_Manager

Scope

This method is applicable for the determination of selected perfluoroether- and perfluoroalkyl-carboxylic and sulfonic acids in aqueous samples to include potable and non-potable waters. The compounds analyzed in this method are listed in the table below. The most current MDLs and LOQs are listed in the LIMS.

Analyte	Acronym	CAS#
PFO5DA C ₇ HF ₁₃ O ₇ (aka TAFN4)	PFO5DA	39492-91-6
PFESA Byproduct 1 C ₇ HF ₁₃ O ₅ S	PFESA-B1	29311-67-9
PFO4DA C ₆ HF ₁₁ O ₆	PFO4DA	39492-90-5
PFO2HxA C ₄ HF ₇ O ₄	PFO2HxA	39492-88-1
PFESA Byproduct 2 C ₇ H ₂ F ₁₄ O ₅ S	PFESA-B2	749836-20-2
PFECA-G C ₇ HF ₁₃ O ₃	PFECA-G	801212-59-9
PFO3OA C ₅ HF ₉ O ₅	PFO3OA	39492-89-2
PFMOAA C ₃ HF ₅ O ₃	PFMOAA	674-13-5
HFPO-DA C ₆ HF ₁₁ O ₃	HFPODA	13252-13-6
PFHpA C ₇ HF ₁₃ O ₂	PFHpA	375-85-9
R-EVE C ₈ H ₂ F ₁₂ O ₅	R-EVE	NA
Byproduct 4 C ₇ H ₂ F ₁₂ O ₆ S	Byproduct 4	NA
Byproduct 5 C ₇ H ₃ F ₁₁ O ₇ S	Byproduct 5	NA
NVHOS C ₄ H ₂ F ₈ O ₄ S	NVHOS	1132933-86-8
PFECA B C ₅ HF ₉ O ₄	PFECA B	151772-58-6
PES C ₄ HF ₉ O ₄ S	PES	113507-82-7
Hydro-EVE Acid C ₈ H ₂ F ₁₄ O ₄	Hydro-EVE Acid	773804-62-9
EVE Acid C ₈ HF ₁₃ O ₄	EVE Acid	69087-46-3
Byproduct 6 C ₆ H ₂ F ₁₂ O ₄ S	Byproduct 6	NA

 Document number: T-PFAS-WI20127 Old Reference:	Always check on-line for validity. Client Specific: Table 3 Compounds by Direct Injection Using LC/MS/MS	Level:  Work Instruction
Version: 3		Organisation level: 5-Sub-BU
Approved by: XL3S Effective Date 05-JUN-2020	Document users: 5_EUUSLA_PFAS_Manager, 6_EUUSLA_PFAS_Analyst, 6_EUUSLA_PFAS_Data_Reviewers, 6_EUUSLA_PFAS_Management_Team, 6_EUUSLA_PFAS_Sample_Prep	Responsible: 5_EUUSLA_PFAS_Manager

Basic Principles

5 mL aqueous sample is diluted to 10 mL with [REDACTED] followed by analysis by LC/MS/MS operated in negative electrospray ionization (ESI) mode for detection and quantification of the analytes. Quantitative analysis is performed using external standard calibration.

Interferences

Compounds which have similar structures to the compounds of interest and similar molecular weights would potentially interfere. Method interferences may be caused by contaminants in solvents, reagents (including reagent water), sample bottles and caps, and other sample processing hardware that lead to discrete artifacts and/or elevated baselines in the chromatograms. The analytes in this method can also be found in many common laboratory supplies and equipment, such as PTFE (polytetrafluoroethylene) products, LC solvent lines, methanol, aluminum foil, etc. A laboratory blank is performed with each batch of samples to demonstrate that the extraction system is free of contaminants.



Precaution to Minimize Method Interference

1. LC system components contain many of the target analytes. To minimize the background PFAS peaks, PTFE solvent frits and tubing are replaced by PEEK™ solvent frits and tubing where possible.
2. A precolumn, Phenomenex Luna, 30 x 2 mm, 5 µm C18 column, is installed before the injection valve to separate PFAS in standards/samples from those from the LC system and mobile phases.
3. PFAS standards, extracts, and samples should not come in contact with any glass containers as these analytes can potentially adsorb to glass surfaces. PFAS analytes and internal standards commercially purchased in glass ampules are acceptable; however, all subsequent transfers or dilutions performed by the analyst must be prepared and stored in polypropylene containers.

Safety Precautions and Waste Handling

See *Chemical Hygiene Plan* for general information regarding employee safety, waste management, and pollution prevention.

The toxicity or carcinogenicity of each reagent used in this method has not been precisely defined. PFOA has been described as "likely to be carcinogenic to humans". Each chemical should be treated as a potential health hazard and exposure to these chemicals should be minimized.

 Document number: T-PFAS-WI20127 Old Reference:	Always check on-line for validity. Client Specific: Table 3 Compounds by Direct Injection Using LC/MS/MS	Level:  Work Instruction
Version: 3		Organisation level: 5-Sub-BU
Approved by: XL3S Effective Date 05-JUN-2020	Document users: 5_EUUSLA_PFAS_Manager, 6_EUUSLA_PFAS_Analyst, 6_EUUSLA_PFAS_Data_Reviewers, 6_EUUSLA_PFAS_Management_Team, 6_EUUSLA_PFAS_Sample_Prep	Responsible: 5_EUUSLA_PFAS_Manager

Exposure to these chemicals must be reduced to the lowest possible level by whatever means available, such as fume hoods, lab coats, safety glasses, and gloves. Gloves, lab coats, and safety glasses should be worn when preparing standards and handling samples. Avoid inhaling solvents and chemicals and getting them on the skin. Wear gloves when handling neat materials. When working with acids and bases, take care not to come in contact and to wipe any spills. Always add acid to water when preparing reagents containing concentrated acids.

All laboratory waste is accumulated, managed, and disposed of in accordance with all Federal, State, and local laws and regulations. All solvent waste and extracts are collected in approved solvent waste containers in the laboratory and subsequently emptied by personnel trained in hazardous waste disposal into the lab-wide disposal facility. HPLC vials are disposed of in the lab container for waste vials, and subsequently lab packed. Any solid waste material (disposable pipettes and broken glassware, etc.) may be disposed of in the normal solid waste collection containers.

Personnel Training and Qualifications

All personnel performing this procedure must have documentation of reading, understanding, and agreeing to follow the current version of this SOP and an annual documented Demonstration of Capability (DOC).

Each chemist performing the extraction must work with an experienced employee for a period of time until they can independently perform the extraction. Also, several batches of sample extractions must be performed under the direct observation of another experienced chemist to assure the trainee is capable of independent preparation. Proficiency is measured through a documented Initial Demonstration of Capability (IDOC).



Each LC/MS/MS analyst must work with an experienced employee for a period of time until they can independently calibrate the LC/MS/MS, review and process data, and perform maintenance procedures. Proficiency is measured through a documented Initial Demonstration of Capability (IDOC).

The IDOC and DOC consist of four laboratory control samples (or alternatively, one blind sample for the DOC) that is carried through all steps of the extraction and meets the defined acceptance criteria for the LCS/LCSD. The criteria include the calculation of mean accuracy and standard deviation.

Sample Collection, Preservation, and Handling

A. Sample Collection

The samples are collected in polypropylene (PP) or high density polyethylene (HDPE) bottles as per the client's sample collection protocols for submission to the laboratory for analysis.

	Always check on-line for validity. Client Specific: Table 3 Compounds by Direct Injection Using LC/MS/MS	Level:  Work Instruction
Document number: T-PFAS-WI20127		Organisation level: 5-Sub-BU
Old Reference:		Responsible: 5_EUUSLA_PFAS_Manager
Version: 3	Document users: 5_EUUSLA_PFAS_Manager, 6_EUUSLA_PFAS_Analyst, 6_EUUSLA_PFAS_Data_Reviewers, 6_EUUSLA_PFAS_Management_Team, 6_EUUSLA_PFAS_Sample_Prep	
Approved by: XL3S Effective Date 05-JUN-2020		

NOTE: PFAS contamination during sampling can occur from a number of common sources, such as food packaging and certain foods and beverages. Proper hand washing and wearing nitrile gloves will aid in minimizing this type of accidental contamination of the samples.



B. Sample Storage and Shipment

1. Samples must be chilled during shipment and must not exceed 10°C during the first 48 hours after collection. Sample temperature must be confirmed to be at or below 10°C when the samples are received at the laboratory.
2. Samples stored in the lab must be held at a temperature of 0° to 6°C, not frozen, until extraction.
3. Water samples should be prepared within 28 days.

Apparatus and Equipment

A. Apparatus

1. 250-mL HDPE bottles: Scientific Specialties; # 334008-blk-1, or equivalent.
2. Centrifuge tubes – 15-mL conical polypropylene with polypropylene screw caps; FisherScientific, Cat. No. 05-539-5 or equivalent
3. 10-mL polypropylene volumetric flask, class A – FisherScientific, Cat. No. S02288 or equivalent.
4. Polypropylene bottles for reagent storage: 1000mL, Fisher; Cat. No. 02896F.
5. Analytical Balance – Capable of weighing to 0.0001 g
6. Top-Loading Balance – Capable of weighing to 0.01 g
7. Auto Pipettes – Eppendorf; capable of accurately dispensing 500µL – 10,000µL
8. Auto Pipettes – Eppendorf; capable of accurately dispensing 50µL – 1000µL.
9. Polypropylene pipette tips: 0-200µL. Fisher; Cat. No. 02-681-135
10. Polypropylene pipette tips: 101-1000µL. Fisher, Cat. No. 02-707-508
11. Vortex mixer, variable speed, Fisher Scientific or equivalent
12. Reagent Water Purification System: Capable of producing ultrapure “Type 1/Milli-Q”-grade water from in-house deionized water system. Millipore SAS; Cat. No. FTPF08831.

	Always check on-line for validity. Client Specific: Table 3 Compounds by Direct Injection Using LC/MS/MS	Level: Work Instruction 
Document number: T-PFAS-WI20127		Organisation level: 5-Sub-BU
Old Reference:		Responsible: 5_EUUSLA_PFAS_Manager
Version: 3	Document users: 5_EUUSLA_PFAS_Manager, 6_EUUSLA_PFAS_Analyst, 6_EUUSLA_PFAS_Data_Reviewers, 6_EUUSLA_PFAS_Management_Team, 6_EUUSLA_PFAS_Sample_Prep	
Approved by: XL3S Effective Date 05-JUN-2020		

13. Waters 9mm vial kit pack with cap and PTFE/Sil Septa, catalog number 16005660CV, or equivalent

14. Syringe filter - Acrodisc, Syringe Filter, GHP, 13 mm, 0.2 µm, Aqueous, 100/pkg, Part # WAT097962.

15. EMD Millipore MColorpHastpH test strips and indicator paper, Fisher Scientific, Cat# M1095350001.

B. Equipment

1. AB Sciex Triple Quad 4500 Turbo V Ion Source

ExionLC Controller
 ExionLC AC Pump
 ExionLC AC Autosampler
 Exion AC Column Oven
 Data system – Analyst 1.6.3

2. AB Sciex Triple Quad 5500 Turbo V Ion Source

ExionLC Controller
 ExionLC AC Pump
 ExionLC AC Autosampler
 Exion AC Column Oven
 Data system – Analyst 1.6.3

3. HPLC columns



- a. Analytical column-Gemini 3µm C18, 50 x 3 mm, Phenomenex Cat# 00B-4439-YO or equivalent
- b. Pre-column- Luna, 5 µm C18, 30 x 2 mm, Phenomenex Cat# 00A-4252-B0, or equivalent

Reagents and Standards

All solvents, acids, and bases are stored in glass bottles in flammable proof cabinets or pressure resistant steel drums. Solvents, acids, and bases are stored at ambient temperature for up to 1 year. All non-solvents are stored according to manufacturer's storage conditions.

A. Reagents:

1. XXXXXXXXXX – Honeywell Burdick and Jackson "Chromasolv LC-MS" grade or equivalent

 Document number: T-PFAS-WI20127 Old Reference:	Always check on-line for validity. Client Specific: Table 3 Compounds by Direct Injection Using LC/MS/MS	Level:  Work Instruction
Version: 3		Organisation level: 5-Sub-BU
Approved by: XL3S Effective Date 05-JUN-2020	Document users: 5_EUUSLA_PFAS_Manager, 6_EUUSLA_PFAS_Analyst, 6_EUUSLA_PFAS_Data_Reviewers, 6_EUUSLA_PFAS_Management_Team, 6_EUUSLA_PFAS_Sample_Prep	Responsible: 5_EUUSLA_PFAS_Manager

2. [REDACTED] – Fisher Scientific, Optima or equivalent

3. [REDACTED] – HPLC grade or equivalent

4. [REDACTED] – Weigh $1.54 \pm 0.01\text{g}$ [REDACTED] into a 1L glass bottle. Add 1 L Milli-Q water and mix well. The solution is prone to volatility losses and is replaced weekly. Store at room temperature.

5. [REDACTED] - Dissolve 3.08 grams of [REDACTED] in 10 grams of Milli-Q water. Dilute to 2L in 2L glass bottle with [REDACTED].

6. [REDACTED] for preparing sample dilutions.

7. Sulfuric acid (H_2SO_4), 1N (0.5M), Acros Organics part number 124240010

8. Potassium hydroxide (KOH) (8N): Acros Organics; 380625000

9. Working KOH solution for pH adjustment (0.1M): In a 100-mL volumetric flask add approximately 75 mL of MQ water. Add 1.25mL 8N KOH to the flask and bring to final volume of 100 mL with MQ water. Stable 6 months. Store at room temp.

10. Working H_2SO_4 solution for pH adjustment (0.1M): In a 100-mL volumetric flask add approximately 50 mL of MQ water. Add 20mL 0.5M H_2SO_4 to the flask and bring to final volume 100 mL with MQ water. Stable 6 months. Store at room temp.

B. Standards



1. All target analytes, except HFPODA and PFHpA were provided by Chemours as certified solutions at 0.1 % by weight. HFPODA and PFHpA were purchased from Wellington as certified solutions at 50,000 ng/mL. Stocks are stored in a refrigerator at 0-6C.

2. Isotope dilution analyte (IDA) solutions purchased from Wellington (or other reputable vendor) at 50,000 ng/mL.

3. Standard solutions from vendors may be purchased in glass ampules, but all subsequent transfers, dilutions and storage vessels should be polypropylene (PP) or high density polyethylene (HDPE).

C. Calibration Standards:

Stock standards and solutions are stored in accordance with the manufacturer recommended storage conditions and expiration dates. Intermediate and calibration standards are stored in refrigerator and expire after 6 months.

	Always check on-line for validity.	Level:			
	Client Specific: Table 3 Compounds by Direct Injection Using LC/MS/MS	Work Instruction			
		Document number: T-PFAS-WI20127			
		Old Reference:			
Version: 3		Organisation level: 5-Sub-BU			
Approved by: XL3S Effective Date 05-JUN-2020	Document users: 5_EUUSLA_PFAS_Manager, 6_EUUSLA_PFAS_Analyst, 6_EUUSLA_PFAS_Data_Reviewers, 6_EUUSLA_PFAS_Management_Team, 6_EUUSLA_PFAS_Sample_Prep	Responsible: 5_EUUSLA_PFAS_Manager			



1. IDA Standard Solution

IDA Working Solution (13C4-PFHpA and 13C3-HFPODA) - dilute 0.02 mL of each IDA compound stock solutions purchased from Wellington Labs as 50,000 ng/mL solutions to 10 mL [REDACTED] for a 100 ng/mL solution. Other dilutions schemes may be used based on the volume of IDA working solution required. Store in refrigerator at 0-6C for up to 6 months.

2. Calibration Standards

Calibration and spiking standards are prepared from standard solutions received from Chemours (0.1% by weight) with the exception of HFPODA and PFHpA which are purchased as a 50,000 ng/ml stock solutions.

Parent Solution	Analyte
Client Supplied Individual Stocks at 1,000,000 ng/mL	PFMOAA
	BP4
	R-EVE
	BP5
	NVHOS
	PFO2HXA
	PES
	PFECA-B
	PFO3OA
	Hydro-EVE Acid
	BP6
	PFESA-BP2
	PFECA-G
	PFO4DA
	PFESA-BP1
	EVE Acid
PFO5DA	



	Always check on-line for validity.	Level: 
	Client Specific: Table 3 Compounds by Direct Injection Using LC/MS/MS	Work Instruction
		Document number: T-PFAS-WI20127
		Old Reference:
Version: 3	Document users: 5_EUUSLA_PFAS_Manager, 6_EUUSLA_PFAS_Analyst, 6_EUUSLA_PFAS_Data_Reviewers, 6_EUUSLA_PFAS_Management_Team, 6_EUUSLA_PFAS_Sample_Prep	Organisation level: 5-Sub-BU
Approved by: XL3S Effective Date 05-JUN-2020		Responsible: 5_EUUSLA_PFAS_Manager

a. Prepare 10,000 ng/mL intermediate A in XXXXXXXXXX

Compound	Conc. (ng/mL)	Init. Vol. (mL)	Final Vol. (mL)	Intermediate A Conc. (ng/mL)
PFMOAA	1 000 000	0.1	10	10 000
BP4	1 000 000	0.1	10	10 000
R-EVE	1 000 000	0.1	10	10 000
BP5	1 000 000	0.1	10	10 000
NVHOS	1 000 000	0.1	10	10 000
PFO2HXA	1 000 000	0.1	10	10 000
PES	1 000 000	0.1	10	10 000
PFECA-B	1 000 000	0.1	10	10 000
PFO3OA	1 000 000	0.1	10	10 000
Hydro-EVE Acid	1 000 000	0.1	10	10 000
BP6	1 000 000	0.1	10	10 000
PFESA-BP2	1 000 000	0.1	10	10 000
PFECA-G	1 000 000	0.1	10	10 000
PFO4DA	1 000 000	0.1	10	10 000
PFESA-BP1	1 000 000	0.1	10	10 000
EVE Acid	1 000 000	0.1	10	10 000
PFO5DA	1 000 000	0.1	10	10 000

b. Prepare 100 ng/mL Intermediate B, which includes HFPODA and PFHpA in XXXXXXXXXX:



Compound	Intermediate A/HFPODA & PFHpA stock Conc. (ng/mL)	Init. Vol. (mL)	Final Vol. (mL)	Intermediate B Conc. (ng/mL)
PFMOAA	10 000	0.1	10	100
BP4	10 000	0.1	10	100
R-EVE	10 000	0.1	10	100
BP5	10 000	0.1	10	100

	Always check on-line for validity.	Level: 
	Client Specific: Table 3 Compounds by Direct Injection Using LC/MS/MS	Work Instruction
	Document number: T-PFAS-WI20127	Organisation level: 5-Sub-BU
	Old Reference:	Responsible: 5_EUUSLA_PFAS_Manager
Version: 3	Document users: 5_EUUSLA_PFAS_Manager, 6_EUUSLA_PFAS_Analyst, 6_EUUSLA_PFAS_Data_Reviewers, 6_EUUSLA_PFAS_Management_Team, 6_EUUSLA_PFAS_Sample_Prep	
Approved by: XL3S Effective Date 05-JUN-2020		

Compound	Intermediate A/HFPODA & PFHpA stock Conc. (ng/mL)	Init. Vol. (mL)	Final Vol. (mL)	Intermediate B Conc. (ng/mL)
NVHOS	10 000	0.1	10	100
PFO2HXA	10 000	0.1	10	100
PFHpA	50 000	0.02	10	100
PES	10 000	0.1	10	100
PFECA-B	10 000	0.1	10	100
PFO3OA	10 000	0.1	10	100
HFPODA	50 000	0.02	10	100
Hydro-EVE Acid	10 000	0.1	10	100
BP6	10 000	0.1	10	100
PFESA-BP2	10 000	0.1	10	100
PFECA-G	10 000	0.1	10	100
PFO4DA	10 000	0.1	10	100
PFESA-BP1	10 000	0.1	10	100
EVE Acid	10 000	0.1	10	100
PFO5DA	10 000	0.1	10	100

c. Prepare 1 ng/mL Intermediate C in XXXXXXXXXX:



Compound	Intermediate B Conc. (ng/mL)	Init. Vol. (mL)	Final Vol. (mL)	Intermediate C Conc. (ng/mL)
PFMOAA	100	0.1	10	1
BP4	100	0.1	10	1
R-EVE	100	0.1	10	1
BP5	100	0.1	10	1
NVHOS	100	0.1	10	1
PFO2HXA	100	0.1	10	1

	Always check on-line for validity.	Level: 
	Client Specific: Table 3 Compounds by Direct Injection Using LC/MS/MS	Work Instruction
	Document number: T-PFAS-WI20127	
	Old Reference:	
Version: 3		Organisation level: 5-Sub-BU
Approved by: XL3S Effective Date 05-JUN-2020	Document users: 5_EUUSLA_PFAS_Manager, 6_EUUSLA_PFAS_Analyst, 6_EUUSLA_PFAS_Data_Reviewers, 6_EUUSLA_PFAS_Management_Team, 6_EUUSLA_PFAS_Sample_Prep	Responsible: 5_EUUSLA_PFAS_Manager

Compound	Intermediate B Conc. (ng/mL)	Init. Vol. (mL)	Final Vol. (mL)	Intermediate C Conc. (ng/mL)
PFHpA	100	0.1	10	1
PES	100	0.1	10	1
PFECA-B	100	0.1	10	1
PFO3OA	100	0.1	10	1
HFPODA	100	0.1	10	1
Hydro-EVE Acid	100	0.1	10	1
BP6	100	0.1	10	1
PFESA-BP2	100	0.1	10	1
PFECA-G	100	0.1	10	1
PFO4DA	100	0.1	10	1
PFESA-BP1	100	0.1	10	1
EVE Acid	100	0.1	10	1
PFO5DA	100	0.1	10	1



d. Prepare Calibration Standards in XXXXXXXXXX

	CAL8		CAL7 CAL6 CAL5 CAL4 CAL3 CAL2 CAL1							
	Initial Volume Intermediate B (mL)	0.5	Initial Volume Intermediate C (mL)	0.1	0.05	0.025	0.01	0.005	0.002	0.001
	Final Volume (mL)	10	Final Volume (mL)	10	10	10	10	10	10	10
Compound	Intermediate B Conc. (ng/mL)	CAL8	Intermediate C Conc. (ng/mL)	CAL7	CAL6	CAL5	CAL4	CAL3	CAL2	CAL1
PFMOAA	100	0.5	1	0.1	0.05	0.025	0.01	0.005	0.002	0.001

	Always check on-line for validity.						Level:		
	Client Specific: Table 3 Compounds by Direct Injection Using LC/MS/MS						Work Instruction		
	Old Reference:		Organisation level: 5-Sub-BU						
Version: 3		Document users: 5_EUUSLA_PFAS_Manager, 6_EUUSLA_PFAS_Analyst, 6_EUUSLA_PFAS_Data_Reviewers, 6_EUUSLA_PFAS_Management_Team, 6_EUUSLA_PFAS_Sample_Prep						Responsible: 5_EUUSLA_PFAS_Manager	
Approved by: XL3S Effective Date 05-JUN-2020									

BP4	100	0.5	1	0.1	0.05	0.025	0.01	0.005	0.002	0.001
R-EVE	100	0.5	1	0.1	0.05	0.025	0.01	0.005	0.002	0.001
BP5	100	0.5	1	0.1	0.05	0.025	0.01	0.005	0.002	0.001
NVHOS	100	0.5	1	0.1	0.05	0.025	0.01	0.005	0.002	0.001
PFO2HXA	100	0.5	1	0.1	0.05	0.025	0.01	0.005	0.002	0.001
PFHpA	100	0.5	1	0.1	0.05	0.025	0.01	0.005	0.002	0.001
PES	100	0.5	1	0.1	0.05	0.025	0.01	0.005	0.002	0.001
PFECA-B	100	0.5	1	0.1	0.05	0.025	0.01	0.005	0.002	0.001
PFO3OA	100	0.5	1	0.1	0.05	0.025	0.01	0.005	0.002	0.001
HFPODA	100	0.5	1	0.1	0.05	0.025	0.01	0.005	0.002	0.001
Hydro-EVE Acid	100	0.5	1	0.1	0.05	0.025	0.01	0.005	0.002	0.001
BP6	100	0.5	1	0.1	0.05	0.025	0.01	0.005	0.002	0.001
PFESA-B2	100	0.5	1	0.1	0.05	0.025	0.01	0.005	0.002	0.001
PFECA-G	100	0.5	1	0.1	0.05	0.025	0.01	0.005	0.002	0.001
PFO4DA	100	0.5	1	0.1	0.05	0.025	0.01	0.005	0.002	0.001
PFESA-B1	100	0.5	1	0.1	0.05	0.025	0.01	0.005	0.002	0.001
EVE Acid	100	0.5	1	0.1	0.05	0.025	0.01	0.005	0.002	0.001
PFO5DA	100	0.5	1	0.1	0.05	0.025	0.01	0.005	0.002	0.001
	IDA Working Solution									
13C3-PFHpA	100	0.25		0.25	0.25	0.25	0.25	0.25	0.25	0.25
13C4-HFPODA	100	0.25		0.25	0.25	0.25	0.25	0.25	0.25	0.25

3. Working native spiking solution



	Always check on-line for validity.	Level:		
	Client Specific: Table 3 Compounds by Direct Injection Using LC/MS/MS	Work Instruction		
		Document number: T-PFAS-WI20127		Organisation level: 5-Sub-BU
		Old Reference:		Responsible: 5_EUUSLA_PFAS_Manager
Version: 3	Document users: 5_EUUSLA_PFAS_Manager, 6_EUUSLA_PFAS_Analyst, 6_EUUSLA_PFAS_Data_Reviewers, 6_EUUSLA_PFAS_Management_Team, 6_EUUSLA_PFAS_Sample_Prep			
Approved by: XL3S Effective Date 05-JUN-2020				

Working Native Spike Solution is prepared by placing 0.25 mL of Intermediate B from standard preparation into a 10 mL volumetric flask and bringing to volume with [REDACTED]. Store in refrigerator at 0-6C for up to 6 months.

Analyte	Native Spike Solution Concentration (ppb)
PFMOAA	2.5
BP4	2.5
R-EVE	2.5
BP5	2.5
NVHOS	2.5
PFO2HXA	2.5
PFHpA	2.5
PES	2.5
PFECA-B	2.5
PFO3OA	2.5
HFPODA	2.5
Hydro-EVE Acid	2.5
BP6	2.5
PFESA-BP2	2.5
PFECA-G	2.5
PFO4DA	2.5
PFESA-BP1	2.5
EVE Acid	2.5
PFO5DA	2.5

Calibration

A. Initial Calibration

	Always check on-line for validity. Client Specific: Table 3 Compounds by Direct Injection Using LC/MS/MS	Level:  Work Instruction
Document number: T-PFAS-WI20127		Organisation level: 5-Sub-BU
Old Reference:		Responsible: 5_EUUSLA_PFAS_Manager
Version: 3	Document users: 5_EUUSLA_PFAS_Manager, 6_EUUSLA_PFAS_Analyst, 6_EUUSLA_PFAS_Data_Reviewers, 6_EUUSLA_PFAS_Management_Team, 6_EUUSLA_PFAS_Sample_Prep	
Approved by: XL3S Effective Date 05-JUN-2020		

1. Calibration standards are prepared at 0.001 ppb, 0.002 ppb, 0.005 ppb, 0.01 ppb, 0.025 ppb, 0.05 ppb, 0.1 ppb, and 0.5 ppb. A minimum of 5 points are required for a linear curve fit. If quadratic curve fit is used, a minimum of 6 points are required.

2. Fit the curve with a linear through zero or linear with a concentration weighing factor of $1/x$ or quadratic regression with a concentration weighing factor $1/x^2$.

3. Initial calibration acceptance criteria

a. The R value for each calibration curve must be ≥ 0.995 for each analyte.

b. The R^2 value for each calibration curve must be ≥ 0.99 for each analyte.

If the criteria are not met, the source of the problem must be determined and corrected. Situations may exist where the initial calibration can be used. In those cases, the data will be reported with a qualifying comment.

4. Initial Calibration Verification (ICV)

2nd source standards are not available. A separately prepared standard at a final concentration of 0.05 ppb is analyzed as the ICV. The calculated amount for each analyte must be within $\pm 30\%$ of the true value with the exception of PFO5DA, Byproduct 4, Byproduct 5, and R-EVE. The calculated amount for PFO5DA, Byproduct 4, Byproduct 5, and R-EVE must be within $\pm 50\%$ of the true value.

B. Continuing calibration



1. Once the calibration curve has been established, the continuing accuracy must be verified by analysis of a continuing calibration verification (CCV) standard every ten samples and at the end of the analysis sequence.

The CCV run after the initial calibration must be at the 0.01 ppb level.

2. Acceptance criteria

The calculated amount for each compound in the CCV standard must be within $\pm 30\%$ of the true value with the exception of PFO5DA, Byproduct 4, Byproduct 5, and R-EVE. The calculated amount for PFO5DA, Byproduct 4, Byproduct 5, and R-EVE must be within $\pm 50\%$ of the true value. Samples that are not bracketed by acceptable CCV analyses must be reanalyzed. If CCV fails, a new initial calibration will be analyzed.

Procedure

	Always check on-line for validity. Client Specific: Table 3 Compounds by Direct Injection Using LC/MS/MS	Level:  Work Instruction
Document number: T-PFAS-WI20127		
Old Reference:		
Version: 3		Organisation level: 5-Sub-BU
Approved by: XL3S Effective Date 05-JUN-2020	Document users: 5_EUUSLA_PFAS_Manager, 6_EUUSLA_PFAS_Analyst, 6_EUUSLA_PFAS_Data_Reviewers, 6_EUUSLA_PFAS_Management_Team, 6_EUUSLA_PFAS_Sample_Prep	Responsible: 5_EUUSLA_PFAS_Manager

A. Sample Preparation

1. Check pH of the sample with pH paper to verify sample pH is 6-8. If necessary, use dilute KOH or H₂SO₄ to adjust pH in the sample container.
2. Using auto pipette, pipet 5 mL of MQ water(blank) or water sample into 15 mL centrifuge tube.
3. Using an autopipette pipet 0.025 mL of IDA Spiking Solution to each sample and QC centrifuge tube.
4. Using auto pipette, add 5 mL of [REDACTED] to sample tube. Use vortex to mix. The resulting solution is a 2X dilution of the sample.
5. Load 3 mL plastic syringe with about 2 mL of diluted sample. Attach GHP syringe filter. Place filter over opening of vial insert and filter about 0.200 mL into insert.
6. Cap autosampler vial and submit for LC/MS/MS analysis.



Dilution of target analytes is required when the calculated concentration exceeds the calibration range of the system. See example below.

100X dilution example:

- a) Using auto pipette, add 9.8 mL of [REDACTED] to a 15 mL centrifuge tube.
- b) Add 0.200 mL of the 2X sample dilution.
- c) Vortex to mix thoroughly.
- d) The resulting solution is a 100X dilution of the sample. Complete sample preparation with steps 4 and 5 above.

B. Matrix Spike/LCS Preparation

1. Check pH of the sample with pH paper to verify sample pH is 6-8. If necessary, use dilute KOH or H₂SO₄ to adjust pH in the sample container.
2. Using auto pipette, pipet 5 mL of MQ water(LCS) or water sample(MS) into 15 mL centrifuge tube.
3. Add 0.05 mL of the native spiking solution.
4. Add 0.025 mL of the IDA Spiking Solution to each centrifuge tube.

	Always check on-line for validity. Client Specific: Table 3 Compounds by Direct Injection Using LC/MS/MS	Level:  Work Instruction
Document number: T-PFAS-WI20127		
Old Reference:		
Version: 3		Organisation level: 5-Sub-BU
Approved by: XL3S Effective Date 05-JUN-2020	Document users: 5_EUUSLA_PFAS_Manager, 6_EUUSLA_PFAS_Analyst, 6_EUUSLA_PFAS_Data_Reviewers, 6_EUUSLA_PFAS_Management_Team, 6_EUUSLA_PFAS_Sample_Prep	Responsible: 5_EUUSLA_PFAS_Manager

5. Using auto pipette, add 5 mL of [REDACTED] to sample tube. Use vortex to mix. The resulting solution is a 2X dilution of the sample.

6. Load 3 mL plastic syringe with about 2 mL of diluted sample. Attach GHP syringe filter. Place filter over opening of vial insert and filter about 0.200 mL into insert.

7. Cap autosampler vial and submit for LC/MS/MS analysis.

C. LC/MS/MS Analysis

1. Tuning and Chromatographic conditions for LC/MS/MS Analysis

Refer to the instrument manufacturer's instructions for tuning and conditions. These values are stored in the tune file for future reference and may not need to be changed unless loss of response is noted.

See the AB Sciex (4000 / 4500) Acquisition, Quantitation, Gradient, and detector condition files for the most up to date chromatographic conditions. Modifications to these conditions can be made at the discretion of the analyst to improve resolution or the chromatographic process.



2. Acquisition method: See [Attachment 1](#)

3. Load sample vials containing standards, quality control samples, and sample extracts into autosampler tray. Allow the instrument adequate time to equilibrate to ensure the mass spec and LC have reached operating conditions (approximately 5 minutes) before the first injection. Analyze several solvent blanks clean the instrument prior to sample acquisition and allow it to stabilize.

4. After the initial calibration, inject a solvent blank, followed by the CCV at 0.1 ppb, and samples. Bracket each set of ten samples with a CCV standard. CAL3, CAL4 and CAL5 are alternated.

5. After injections are completed, check all CCV recoveries and absolute areas to make sure they are within method control limits. See Calibration section B.2 for acceptance criteria. Process each chromatogram and closely evaluate all integrations, baseline anomalies, and retention time differences. If manual integrations are performed, they must be documented and a reason given for the change in integrations. The manual integrations are documented during data processing and all original integrations are reported at the end of the sample PDF file with the reason for manual integration clearly listed.

6. Quantitate results for the method blank. No target analytes at or above the reporting limit may be found in the method blank for acceptable batch results. If a target analyte is detected in the method blank but not detected in the sample, the data is reported. If a target analyte is detected in the method blank at a concentration greater than the reporting limit and also in the sample, the sample must be reprepared. If the target analyte in the sample is detected at a concentration greater than 10 times the amount detected in the method blank, the data is reported.

	Always check on-line for validity. Client Specific: Table 3 Compounds by Direct Injection Using LC/MS/MS	Level: Work Instruction 
Document number: T-PFAS-WI20127		Organisation level: 5-Sub-BU
Old Reference:		Responsible: 5_EUUSLA_PFAS_Manager
Version: 3	Document users: 5_EUUSLA_PFAS_Manager, 6_EUUSLA_PFAS_Analyst, 6_EUUSLA_PFAS_Data_Reviewers, 6_EUUSLA_PFAS_Management_Team, 6_EUUSLA_PFAS_Sample_Prep	
Approved by: XL3S Effective Date 05-JUN-2020		

7. Calculate the recoveries of spiked analytes for the LCS, and matrix spike (MS) by comparing concentrations observed to the true values. The QC acceptance limits for LCS and MS recovery are 70 to 130% for each analyte with the exception of PFO5DA, Byproduct 4, Byproduct 5, and R-EVE. The QC acceptance limits for LCS and MS recovery are 50 to 150% for PFO5DA, Byproduct 4, Byproduct 5, and R-EVE. The QC acceptance limit for the relative percent difference (%RPD) between unspiked sample and the duplicate sample is $\leq 25\%$ at mid and high range concentrations and $\leq 50\%$ at the minimum reporting limit. If LCS recoveries are acceptable, proceed to sample quantitation. If the LCS recoveries are unacceptable, the samples associated with the LCS may need to be reanalyzed. If LCS recoveries are above the QC acceptance limits, and there are no positive detections in the sample, the data may be reported. A comment must be added to the analytical report.

8. Compare the retention times of all of the analytes to the retention times of the calibration standards. The relative retention times should not vary by more than 0.2 retention time units.

9. The CAL1 standard is used when assessing the correctness of the computer generated peak integrations. For results that have responses at or near the CAL1, the analysts will calculate 1/2 of the area ratio of that compound in the CAL1 standard. If the area ratio for the compound in the sample exceeds that 1/2 the area ratio from the CAL1 standard, the peak is reported as a positive detection.

10. If the calculated concentration exceeds the calibration range of the system, dilute the extract with [REDACTED] as described in the Sample Preparation section and reanalyze the diluted sample.

Calculations

A. Analyte Concentration using linear through zero curves (MQ Data processing system)



$$\text{Concentration} = (\text{area} \div \text{slope}) \times \text{Dilution Factor}$$

B. Sample Concentration (used only for aqueous samples using the MultiQuant data processing system on the AB Sciex LC/MS/MS)

$$\text{Sample concentration (ug/l)} = \text{Calc conc} \times (\text{Sample volume} \div \text{Sample weight}) \times \text{DF}$$

C. See [T-PEST-WI9847](#) for additional calculations used to evaluate the calibrations and quality control samples.

Statistical Information/Method Performance

	Always check on-line for validity. Client Specific: Table 3 Compounds by Direct Injection Using LC/MS/MS	Level:  Work Instruction
Document number: T-PFAS-WI20127		Organisation level: 5-Sub-BU
Old Reference:		Responsible: 5_EUUSLA_PFAS_Manager
Version: 3	Document users: 5_EUUSLA_PFAS_Manager, 6_EUUSLA_PFAS_Analyst, 6_EUUSLA_PFAS_Data_Reviewers, 6_EUUSLA_PFAS_Management_Team, 6_EUUSLA_PFAS_Sample_Prep	
Approved by: XL3S Effective Date 05-JUN-2020		

The LCS should contain all compounds of interest. The limits for LCS and MS are defined by the method. LCS, MS, and RPD are compared to the limits stored on the LIMS. Historical data for MSs, LCSs, measurement of uncertainty, is reviewed at least annually. Reporting limits including method detection limits (MDLs) and limits of quantitation (LOQs) are set according to EPA method requirements and are evaluated annually. Refer to [QA-SOP11892](#) for specific guidelines and procedures. Updates to the LIMS are made as needed by the QA Department and only as directed by the supervisor.

Quality Assurance/Quality Control



For each batch of samples extracted, a method blank, an LCS (Milli-Q water spiked with all compounds to be determined carried through the entire procedure) must be extracted. For each sample, an MS and a DUP must be extracted. A batch is defined as the samples to be extracted on any given day, but not to exceed 20 field samples. If more than 20 samples are prepared in a day, an additional batch must be prepared. If any client, state, or agency has more stringent QC or batching requirements, these must be followed instead.

The QC acceptance criteria are specified in the method and are as follows:

1. Blank – Value less than the limit of quantitation
2. LCS – 70% to 130% recovery for all analytes with the exception of PFO5DA, Byproduct 4, Byproduct 5, and R-EVE. The recovery criteria for PFO5DA, Byproduct 4, Byproduct 5, and R-EVE is 50% to 150%.
3. MS – 70% to 130% recovery for all analytes with the exception of PFO5DA, Byproduct 4, Byproduct 5, and R-EVE. The recovery criteria for PFO5DA, Byproduct 4, Byproduct 5, and R-EVE is 50% to 150%.
4. Sample Duplicate RPD (relative percent difference)
 - a. ≤25% at mid and high range concentrations
 - b. ≤50% at the minimum reporting limit

[QA-SOP11892 Determining Method Detection Limits and Limits of Quantitation](#)
[T-PEST-WI9847 Common Equations Used During Chromatographic Analyses](#)
 Attachment: [Attachment 1 - Table 3 Operating Conditions \(doc\)](#)

Attachment:
[Attachment 1 - Table 3 Operating Conditions](#)

 Document number: T-PFAS-WI20127 Old Reference:	Always check on-line for validity. <p style="text-align: center;">Client Specific: Table 3 Compounds by Direct Injection Using LC/MS/MS</p>	Level:  Work Instruction
Version: 3		Organisation level: 5-Sub-BU
Approved by: XL3S Effective Date 05-JUN-2020	Document users: 5_EUUSLA_PFAS_Manager, 6_EUUSLA_PFAS_Analyst, 6_EUUSLA_PFAS_Data_Reviewers, 6_EUUSLA_PFAS_Management_Team, 6_EUUSLA_PFAS_Sample_Prep	Responsible: 5_EUUSLA_PFAS_Manager

End of document

Version history

Version	Approval	Revision information
1	27.SEP.2018	
2	12.APR.2019	
3	05.JUN.2020	

CONFIDENTIAL

Attachment 1

Recommended Instrument Operating Conditions

A. HPLC Conditions (Exion LC)

Column – Phenomenex Gemini 3um C18 110A, 50 X 3.0 mm

Column Temperature = [REDACTED]

Injection Size – [REDACTED]

Mobile Phase Composition	Time	A = [REDACTED]	B = [REDACTED]	Flow Rate (ml/min)
		% A	% B	
Gradient Program	0	95	5	0.2
	0.40	95	5	0.2
	0.60	50	50	0.5
	3.50	5	95	0.5
	6.00	5	95	0.5
	6.25	95	5	0.5
	9.00	95	5	0.5
	9.50	95	5	0.2
	10.0	95	5	0.2

B. Mass Spectrometer Settings (AB Sciex 5500)

1. Mass Spectrometer Interface Settings

MS Interface Mode – ESI Negative Ion, minimum of 10 scans/peak

Ion Spray Voltage (kV) – 4.5

Entrance Potential (V) – 5

Declustering Potential (V) – 25

Desolvation Temp - 600°C

Curtain Gas – 25 psi

Collision Gas – 8 psi

Attachment 1

Mass Spectrometer Settings (AB Sciex 5500) – cont'd.

2. Mass Spectrometer Scan Settings

Compound	Reaction (MRM)	Dwell (msec)	Ent. Pot (V)	Col. Energy (V)	Decluster Pot. (V)	Cell Exit Pot.	Typical RT (Min)
PFMOAA	179 > 85	3-250	-10	-15	-15	-15	2.58
BP4	441 > 241	3-250	-10	-32	-80	-15	2.68
R-EVE	405 > 217	3-250	-10	-25	-60	-15	2.70
BP5	439 > 343	3-250	-10	-35	-80	-15	2.69
NVHOS	297 > 135	3-250	-10	-35	-80	-15	2.93
PFO2HXA	245 > 85	3-250	-10	-15	-10	-15	3.15
PFHpA	363 > 319	3-250	-10	-15	-40	-15	3.83
PES	315 > 135	3-250	-10	-31	-65	-15	3.41
PFECA-B	295 > 201	3-250	-10	-13	-16	-15	3.53
PFO3OA	311 > 85	3-250	-10	-15	-20	-15	3.63
HFPODA	329 > 285	3-250	-10	-8	-10	-15	3.68
HFPODA-169	329 > 169	3-250	-10	-18.50	-10	-15	3.68
Hydro-EVE Acid	427 > 283	3-250	-10	-18	-40	-15	3.85
BP6	397 > 217	3-250	-10	-35	-80	-15	3.85
PFESA-BP2	463 > 263	3-250	-10	-38	-80	-15	3.85
PFECA-G	379 > 185	3-250	-10	-20	-35	-15	3.93
PFO4DA	377 > 85	3-250	-10	-40	-20	-15	4.01
PFESA-BP1	443 > 147	3-250	-10	-32	-70	-15	4.03
EVE Acid	407 > 263	3-250	-12	-14	-40	-15	4.05
PFO5DA	443 > 85	3-250	-10	-37	-7	-15	4.31

Attachment 1

13C3- HFPODA	332 > 287	3-250	-10	-9	-15	-15	3.68
13C4- PFHpA	367 > 322	3-250	-10	-15	-40	-15	3.83

CONFIDENTIAL